Panobinostat in multiple myeloma
Mené au Royaume-Uni sur 57 patients atteints d'un myélome multiple récidivant et/ou réfractaire, cet essai de phase I/II évalue la dose maximale tolérée, l'efficacité, du point de vue du taux de réponse globale, et la toxicité de l'ajout du panobinostat à un traitement combinant bortézomib, thalidomide et dexaméthasone
In this issue of The Lancet Haematology, Rakesh Popat and colleagues1 report on a four-drug combination of panobinostat, bortezomib, thalidomide, and dexamethasone for the treatment of relapsed or refractory multiple myeloma. In this phase 1/2 study, 42 patients (91%) of 46 receiving 20 mg panobinostat (the maximum tolerated dose was not reached) achieved an overall response (ie, a partial response or better) in a population with a median of one previous therapy, justifying further exploration in a randomised phase 2 trial setting.
The Lancet Haematology , commentaire, 2015